Search

Idursulfase

Idursulfase is produced by recombinant DNA technology in a human cell line. … The enzyme contains eight asparagine-linked glycosylation sites occupied by complex oligosaccharide structures.

Reserpine

It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use. … An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria.

Tolazamide

A sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide.

Celecoxib

[A181532] It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998.

Beremagene geperpavec

Developed by Krystal Biotech, it was first approved by the FDA on May 19, 2023, for the treatment of wounds associated with dystrophic epidermolysis bullosa (DEB). … [L46916] DEB is caused by mutations in the _COL7A1_ gene that encodes collagen VII (COL7), a major component of the anchoring fibrils for dermal–epidermal cohesion.

Linoleic acid

Baclofen

Although originally designed in 1962 to treat epilepsy, baclofen was not effective in treating this condition but instead was shown to reduce spasticity in selected patients. … [A245338] Baclofen was reintroduced in 1971 as a treatment for spasticity and was later approved by the FDA in 1977.

Tegafur

When converted and bioactivated to 5-FU, the drug mediates an anticancer activity by inhibiting thymidylate synthase (TS) during the pyrimidine pathway involved in DNA synthesis. 5-FU is listed on the … Tegafur is usually given in combination with other drugs that enhance the bioavailability of the 5-FU by blocking the enzyme responsible for its degradation, or serves to limit the toxicity of 5-FU by

Human Menstrual Blood-derived Stem Cells

ESCs are from the inner cell mass of blastocysts while ASCs are deposited into adult tissues with restricted differentiation potency but also a lack of tumorigenicity. … Because this is a non-invasive way to obtain stem cells, it is simple and easy to obtain the stem cells with an absence of ethical issues that may come from obtaining stem cells of the embryonic kind.

Sotrovimab

Sotrovimab (VIR-7831), also known as GSK4182136, is a monoclonal antibody that can neutralize the SARS-CoV-2 virus. … [L34425, L34430, L34440] However, in April 2022, the FDA removed the EUA for sotrovimab due to the rising COVID-19 cases caused by the Omicron BA.2 sub-variant, where the drug is ineffective.